Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences' stock has experienced significant movements in the past six months. The stock surged over 150% in October 2025 following positive topline results from its registrational trial of Ozekibart (INBRX-109). Between January 10, 2025, and January 8, 2026, the share price increased by 427.94%. In December 2025, Citizens reiterated a "Market Perform" rating on INBX stock, citing concerns about limited data disclosures and a lack of management communication. On January 13, 2026, shares of Inhibrx Biosciences dropped 6.5% during mid-day trading. Earlier, in May 2024, the company's stockholders approved the sale of its INBRX-101 program to Sanofi for $2.0 billion.

There is no readily available information to suggest significant demand seasonality for Inhibrx Biosciences' products and services. The demand for such specialized pharmaceutical products is typically driven by medical need and regulatory approvals rather than seasonal fluctuations.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutics for life-threatening conditions, operating within the Healthcare sector, specifically in the Biotechnology and Biopharmaceutical industry. The company utilizes proprietary modular protein engineering platforms to develop its therapeutic candidates, including INBRX-109 for unresectable or metastatic conventional chondrosarcoma and INBRX-106 for metastatic solid tumors. Previously, INBRX-101 was part of its pipeline before its sale to Sanofi.

Inhibrx Biosciences, Inc. is headquartered in La Jolla, California, United States. The company is involved in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in various international locations, including Australia, the United States, Germany, the United Kingdom, Switzerland, China, and Hong Kong.

In the past year, Inhibrx Biosciences has received a consensus "Reduce" rating from analysts, based on two hold ratings and one sell rating. Concerns have been raised by research firms regarding limited data disclosures and a lack of management communication. The company has a Corporate Code of Conduct and Ethics and a Whistleblower Policy, last updated in December 2025, indicating an emphasis on ethical governance.

Approximately 49.01% to 56.31% of Inhibrx Biosciences, Inc.'s stock is owned by institutional investors, 9.74% by insiders, and 7.30% to 33.94% by public companies and individual investors. Major institutional owners include Viking Global Investors Lp, Perceptive Advisors Llc, Sanofi, HighTower Advisors, LLC, BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, Sofinnova Investments, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Woodline Partners LP. Andreas Halvorsen is noted as owning the most shares.